ライフサイエンスコーパス: dentifrice

1 ice) and 2) placebo group (NSPT plus placebo dentifrice).

2 FMUD and daily use of a triclosan/copolymer dentifrice.

3 s microbiologic counts compared with placebo dentifrice.

4 ce to a positive control triclosan/copolymer dentifrice.

5 iodontal parameters than NSPT plus a placebo dentifrice.

6 the pyrophosphates to become soluble in the dentifrice.

7 may occur when pyrophosphates are added to a dentifrice.

8 f from DH of a zinc-carbonate hydroxyapatite dentifrice.

9 st a commercially available positive control dentifrice (0.30% triclosan/2.0% Gantrez copolymer).

10 sing a double-mask, randomized design, three dentifrices: 1) containing 8% arginine and 1,450 ppm sod

11 n group (NSPT plus medicated 2% atorvastatin dentifrice) and 2) placebo group (NSPT plus placebo dent

12 etate-based dentifrice (group 2), and 29 the dentifrice based on zinc-carbonate hydroxyapatite (group

13 efore, was to determine efficacy of a SrAc2F dentifrice compared with KCl/MFP and a commercially avai

14 biologic effects of a commercially available dentifrice containing aloe vera on the reduction of plaq

15 Cl/MFP and a commercially available fluoride dentifrice containing sodium fluoride/sodium monofluorop

16 have demonstrated efficacy of desensitizing dentifrices containing strontium acetate/sodium fluoride

17 efficacy between 1000- and 2500-ppm-fluoride dentifrices could be detected after 12 months.

18 dentifrice (n = 21) or triclosan-containing dentifrice ([CT] n = 18).

19 ice relative to a positive control triclosan dentifrice for prevention of clinical attachment loss (C

20 e only Food and Drug Administration-approved dentifrice for the treatment of plaque and gingivitis.

21 A secondary objective was to compare the dentifrices for root caries remineralization.

22 First, tetrasodium pyrophosphate in a dentifrice forms a slightly alkaline solution upon oral

23 de and triclosan have been incorporated into dentifrice formulations and have been shown to be effect

24 individuals: 29 received the arginine-based dentifrice (group 1), 27 the strontium acetate-based den

25 ce (group 1), 27 the strontium acetate-based dentifrice (group 2), and 29 the dentifrice based on zin

26 In contrast, control dentifrice had little effect.

27 here is evidence that the use of arginine in dentifrices helps protect against caries.

28 s establish comparable benefits for the SnF2 dentifrice in preventing CAL and root caries versus the

29 % stannous fluoride/sodium hexametaphosphate dentifrice in reducing gingivitis compared to the triclo

30 rice was as effective as the 2 desensitizing dentifrices in alleviating CDS over time.

31 nt study is to assess the effectiveness of a dentifrice medicated with 2% atorvastatin in improving c

32 ly assigned to a toothpaste regimen: control dentifrice (n = 21) or triclosan-containing dentifrice (

33 evaluates the effect of triclosan/copolymer dentifrice on the 6-month clinical response of patients

34 nticalculus component of most tartar control dentifrices on the market today.

35 subjected to FMUD and daily use of a placebo dentifrice or to a test group (n = 15) subjected to FMUD

36 significant potential to be integrated into dentifrices or mouthrinses as an alternative non-fluorid

37 resent study, the use of triclosan/copolymer dentifrice promoted additional clinical benefits in the

38 e the efficacy of a stannous fluoride (SnF2) dentifrice relative to a positive control triclosan dent

39 The comparison among the three dentifrices showed that, after 3 days, there was an impr

40 This study documents that the three tested dentifrices significantly reduced DH after 3-day treatme

41 tifrice was tested versus a positive control dentifrice (sodium fluoride/0.30% triclosan/copolymer) i

42 hosphates have been approved as additives in dentifrices, these compounds along with the increased co

43 % stannous fluoride/sodium hexametaphosphate dentifrice to a positive control triclosan/copolymer den

44 he relative abilities of three desensitizing dentifrices to provide rapid relief of dentin hypersensi

45 n produced in this model with daily fluoride dentifrice treatments.

46 bjects were instructed to use their assigned dentifrice twice daily for 6 weeks.

47 e commercially available fluoride-containing dentifrice was as effective as the 2 desensitizing denti

48 NSPT plus 2% atorvastatin medicated dentifrice was more effective in improving clinical peri

49 % stannous fluoride/sodium hexametaphosphate dentifrice was tested against a commercially available p

50 A 0.454% SnF2/sodium hexametaphosphate dentifrice was tested versus a positive control dentifri

51 tients that were followed up to 8 weeks: all dentifrices were all highly efficacious.

52 All dentifrices were mostly effective to reduce DH: the perc